Professional role
Academic Coordinator, KI-Mayo Collaboration[1]
SE
Dr. Erhardt's role within the Mayo Clinic and Karolinska Institutet (KI) collaboration is to support the continuation and growth of joint initiatives that bridge research and education.
Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression · genomics and clinical phenotyping of mental illness · proteomic signatures associated with symptom severity of first-episode of psychosis
Reviewed sources document Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression, genomics and clinical phenotyping of mental illness, and proteomic signatures associated with symptom severity of first-episode of psychosis. Explore attributed publications and research affiliations.
Explore researchBioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression[1]
genomics and clinical phenotyping of mental illness[1]
proteomic signatures associated with symptom severity of first-episode of psychosis[1]
Sources are listed once and connected to each accepted claim they support. Excerpts preserve the source language used in the review.
10 source claims · Reviewed Sep 9, 2026
Biographical context: Dr. Erhardt's role within the Mayo Clinic and Karolinska Institutet (KI) collaboration is to support the continuation and growth of joint initiatives that bridge research and education.
## Sophie Erhardt, Ph.D. Professor of Experimental Psychiatry, Academic Coordinator, KI-Mayo Collaboration, President, Scandinavian College of Neuropharmacology, Karolinska Institutet, Stockholm, Sweden Mayo Clinic Collaborators: Mark A. Frye, M.D. **Visual description:** Photograph of a smiling woman with blonde hair and glasses, wearing a white coat and seated beside laboratory equipment. Dr. Erhardt's role within the Mayo Clinic and Karolinska Institutet (KI) collaboration is to support the continuation and growth of joint initiatives that bridge research and education. As the partnership celebrates its 30th year in 2024, she has actively contributed to sustaining the collaborative spirit that drives innovation and shared successes between these two leading institutions. For more than a decade, neuroscientists, psychiatrists, psychiatric statistical geneticists, educators and students from Mayo and KI have met to design research projects focused on genomics and clinical phenotyping of mental illness, as well as investigating biologically based mechanisms of disease pathology and treatment response. Students are actively involved in the mentored opportunities. Dr. Erhardt, Professor of Experimental Psychiatry and research group leader for Neuropsychoimmunology at the Department of Physiology and Pharmacology, has led efforts in joint publications focused on Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression and proteomic signatures associated with symptom severity of first-episode of psychosis.
Degree: Ph.D.
## Sophie Erhardt, Ph.D. Professor of Experimental Psychiatry, Academic Coordinator, KI-Mayo Collaboration, President, Scandinavian College of Neuropharmacology, Karolinska Institutet, Stockholm, Sweden Mayo Clinic Collaborators: Mark A. Frye, M.D. **Visual description:** Photograph of a smiling woman with blonde hair and glasses, wearing a white coat and seated beside laboratory equipment. Dr. Erhardt's role within the Mayo Clinic and Karolinska Institutet (KI) collaboration is to support the continuation and growth of joint initiatives that bridge research and education. As the partnership celebrates its 30th year in 2024, she has actively contributed to sustaining the collaborative spirit that drives innovation and shared successes between these two leading institutions. For more than a decade, neuroscientists, psychiatrists, psychiatric statistical geneticists, educators and students from Mayo and KI have met to design research projects focused on genomics and clinical phenotyping of mental illness, as well as investigating biologically based mechanisms of disease pathology and treatment response. Students are actively involved in the mentored opportunities. Dr. Erhardt, Professor of Experimental Psychiatry and research group leader for Neuropsychoimmunology at the Department of Physiology and Pharmacology, has led efforts in joint publications focused on Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression and proteomic signatures associated with symptom severity of first-episode of psychosis.
Identity: Sophie Erhardt, Ph.D.
## Sophie Erhardt, Ph.D. Professor of Experimental Psychiatry, Academic Coordinator, KI-Mayo Collaboration, President, Scandinavian College of Neuropharmacology, Karolinska Institutet, Stockholm, Sweden Mayo Clinic Collaborators: Mark A. Frye, M.D. **Visual description:** Photograph of a smiling woman with blonde hair and glasses, wearing a white coat and seated beside laboratory equipment. Dr. Erhardt's role within the Mayo Clinic and Karolinska Institutet (KI) collaboration is to support the continuation and growth of joint initiatives that bridge research and education. As the partnership celebrates its 30th year in 2024, she has actively contributed to sustaining the collaborative spirit that drives innovation and shared successes between these two leading institutions. For more than a decade, neuroscientists, psychiatrists, psychiatric statistical geneticists, educators and students from Mayo and KI have met to design research projects focused on genomics and clinical phenotyping of mental illness, as well as investigating biologically based mechanisms of disease pathology and treatment response. Students are actively involved in the mentored opportunities. Dr. Erhardt, Professor of Experimental Psychiatry and research group leader for Neuropsychoimmunology at the Department of Physiology and Pharmacology, has led efforts in joint publications focused on Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression and proteomic signatures associated with symptom severity of first-episode of psychosis.
Professional role: Academic Coordinator, KI-Mayo Collaboration
## Sophie Erhardt, Ph.D. Professor of Experimental Psychiatry, Academic Coordinator, KI-Mayo Collaboration, President, Scandinavian College of Neuropharmacology, Karolinska Institutet, Stockholm, Sweden Mayo Clinic Collaborators: Mark A. Frye, M.D. **Visual description:** Photograph of a smiling woman with blonde hair and glasses, wearing a white coat and seated beside laboratory equipment. Dr. Erhardt's role within the Mayo Clinic and Karolinska Institutet (KI) collaboration is to support the continuation and growth of joint initiatives that bridge research and education. As the partnership celebrates its 30th year in 2024, she has actively contributed to sustaining the collaborative spirit that drives innovation and shared successes between these two leading institutions. For more than a decade, neuroscientists, psychiatrists, psychiatric statistical geneticists, educators and students from Mayo and KI have met to design research projects focused on genomics and clinical phenotyping of mental illness, as well as investigating biologically based mechanisms of disease pathology and treatment response. Students are actively involved in the mentored opportunities. Dr. Erhardt, Professor of Experimental Psychiatry and research group leader for Neuropsychoimmunology at the Department of Physiology and Pharmacology, has led efforts in joint publications focused on Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression and proteomic signatures associated with symptom severity of first-episode of psychosis.
Professional role: President, Scandinavian College of Neuropharmacology
## Sophie Erhardt, Ph.D. Professor of Experimental Psychiatry, Academic Coordinator, KI-Mayo Collaboration, President, Scandinavian College of Neuropharmacology, Karolinska Institutet, Stockholm, Sweden Mayo Clinic Collaborators: Mark A. Frye, M.D. **Visual description:** Photograph of a smiling woman with blonde hair and glasses, wearing a white coat and seated beside laboratory equipment. Dr. Erhardt's role within the Mayo Clinic and Karolinska Institutet (KI) collaboration is to support the continuation and growth of joint initiatives that bridge research and education. As the partnership celebrates its 30th year in 2024, she has actively contributed to sustaining the collaborative spirit that drives innovation and shared successes between these two leading institutions. For more than a decade, neuroscientists, psychiatrists, psychiatric statistical geneticists, educators and students from Mayo and KI have met to design research projects focused on genomics and clinical phenotyping of mental illness, as well as investigating biologically based mechanisms of disease pathology and treatment response. Students are actively involved in the mentored opportunities. Dr. Erhardt, Professor of Experimental Psychiatry and research group leader for Neuropsychoimmunology at the Department of Physiology and Pharmacology, has led efforts in joint publications focused on Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression and proteomic signatures associated with symptom severity of first-episode of psychosis.
Professional role: Professor of Experimental Psychiatry
## Sophie Erhardt, Ph.D. Professor of Experimental Psychiatry, Academic Coordinator, KI-Mayo Collaboration, President, Scandinavian College of Neuropharmacology, Karolinska Institutet, Stockholm, Sweden Mayo Clinic Collaborators: Mark A. Frye, M.D. **Visual description:** Photograph of a smiling woman with blonde hair and glasses, wearing a white coat and seated beside laboratory equipment. Dr. Erhardt's role within the Mayo Clinic and Karolinska Institutet (KI) collaboration is to support the continuation and growth of joint initiatives that bridge research and education. As the partnership celebrates its 30th year in 2024, she has actively contributed to sustaining the collaborative spirit that drives innovation and shared successes between these two leading institutions. For more than a decade, neuroscientists, psychiatrists, psychiatric statistical geneticists, educators and students from Mayo and KI have met to design research projects focused on genomics and clinical phenotyping of mental illness, as well as investigating biologically based mechanisms of disease pathology and treatment response. Students are actively involved in the mentored opportunities. Dr. Erhardt, Professor of Experimental Psychiatry and research group leader for Neuropsychoimmunology at the Department of Physiology and Pharmacology, has led efforts in joint publications focused on Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression and proteomic signatures associated with symptom severity of first-episode of psychosis.
Professional role: research group leader for Neuropsychoimmunology
## Sophie Erhardt, Ph.D. Professor of Experimental Psychiatry, Academic Coordinator, KI-Mayo Collaboration, President, Scandinavian College of Neuropharmacology, Karolinska Institutet, Stockholm, Sweden Mayo Clinic Collaborators: Mark A. Frye, M.D. **Visual description:** Photograph of a smiling woman with blonde hair and glasses, wearing a white coat and seated beside laboratory equipment. Dr. Erhardt's role within the Mayo Clinic and Karolinska Institutet (KI) collaboration is to support the continuation and growth of joint initiatives that bridge research and education. As the partnership celebrates its 30th year in 2024, she has actively contributed to sustaining the collaborative spirit that drives innovation and shared successes between these two leading institutions. For more than a decade, neuroscientists, psychiatrists, psychiatric statistical geneticists, educators and students from Mayo and KI have met to design research projects focused on genomics and clinical phenotyping of mental illness, as well as investigating biologically based mechanisms of disease pathology and treatment response. Students are actively involved in the mentored opportunities. Dr. Erhardt, Professor of Experimental Psychiatry and research group leader for Neuropsychoimmunology at the Department of Physiology and Pharmacology, has led efforts in joint publications focused on Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression and proteomic signatures associated with symptom severity of first-episode of psychosis.
Research interests: Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression
## Sophie Erhardt, Ph.D. Professor of Experimental Psychiatry, Academic Coordinator, KI-Mayo Collaboration, President, Scandinavian College of Neuropharmacology, Karolinska Institutet, Stockholm, Sweden Mayo Clinic Collaborators: Mark A. Frye, M.D. **Visual description:** Photograph of a smiling woman with blonde hair and glasses, wearing a white coat and seated beside laboratory equipment. Dr. Erhardt's role within the Mayo Clinic and Karolinska Institutet (KI) collaboration is to support the continuation and growth of joint initiatives that bridge research and education. As the partnership celebrates its 30th year in 2024, she has actively contributed to sustaining the collaborative spirit that drives innovation and shared successes between these two leading institutions. For more than a decade, neuroscientists, psychiatrists, psychiatric statistical geneticists, educators and students from Mayo and KI have met to design research projects focused on genomics and clinical phenotyping of mental illness, as well as investigating biologically based mechanisms of disease pathology and treatment response. Students are actively involved in the mentored opportunities. Dr. Erhardt, Professor of Experimental Psychiatry and research group leader for Neuropsychoimmunology at the Department of Physiology and Pharmacology, has led efforts in joint publications focused on Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression and proteomic signatures associated with symptom severity of first-episode of psychosis.
Research interests: genomics and clinical phenotyping of mental illness
## Sophie Erhardt, Ph.D. Professor of Experimental Psychiatry, Academic Coordinator, KI-Mayo Collaboration, President, Scandinavian College of Neuropharmacology, Karolinska Institutet, Stockholm, Sweden Mayo Clinic Collaborators: Mark A. Frye, M.D. **Visual description:** Photograph of a smiling woman with blonde hair and glasses, wearing a white coat and seated beside laboratory equipment. Dr. Erhardt's role within the Mayo Clinic and Karolinska Institutet (KI) collaboration is to support the continuation and growth of joint initiatives that bridge research and education. As the partnership celebrates its 30th year in 2024, she has actively contributed to sustaining the collaborative spirit that drives innovation and shared successes between these two leading institutions. For more than a decade, neuroscientists, psychiatrists, psychiatric statistical geneticists, educators and students from Mayo and KI have met to design research projects focused on genomics and clinical phenotyping of mental illness, as well as investigating biologically based mechanisms of disease pathology and treatment response. Students are actively involved in the mentored opportunities. Dr. Erhardt, Professor of Experimental Psychiatry and research group leader for Neuropsychoimmunology at the Department of Physiology and Pharmacology, has led efforts in joint publications focused on Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression and proteomic signatures associated with symptom severity of first-episode of psychosis.
Research interests: proteomic signatures associated with symptom severity of first-episode of psychosis
## Sophie Erhardt, Ph.D. Professor of Experimental Psychiatry, Academic Coordinator, KI-Mayo Collaboration, President, Scandinavian College of Neuropharmacology, Karolinska Institutet, Stockholm, Sweden Mayo Clinic Collaborators: Mark A. Frye, M.D. **Visual description:** Photograph of a smiling woman with blonde hair and glasses, wearing a white coat and seated beside laboratory equipment. Dr. Erhardt's role within the Mayo Clinic and Karolinska Institutet (KI) collaboration is to support the continuation and growth of joint initiatives that bridge research and education. As the partnership celebrates its 30th year in 2024, she has actively contributed to sustaining the collaborative spirit that drives innovation and shared successes between these two leading institutions. For more than a decade, neuroscientists, psychiatrists, psychiatric statistical geneticists, educators and students from Mayo and KI have met to design research projects focused on genomics and clinical phenotyping of mental illness, as well as investigating biologically based mechanisms of disease pathology and treatment response. Students are actively involved in the mentored opportunities. Dr. Erhardt, Professor of Experimental Psychiatry and research group leader for Neuropsychoimmunology at the Department of Physiology and Pharmacology, has led efforts in joint publications focused on Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression and proteomic signatures associated with symptom severity of first-episode of psychosis.